Sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer
20 July 2026
In patients with previously untreated advanced triple-negative breast cancer, the
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: new data from a Michelangelo Foundation study.
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did not increase the rate of pathological complete remission, mostly influenced by PD-L1 expression.
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as neoadjuvant therapy, with a relevant effect on Ki67
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer
In patients with previously untreated advanced triple-negative breast cancer, the
New data from the NeoTRIPaPDL1 phase III trial show that
Findings from the MASAI Swedish study show consistently more favorable
Fondazione Michelangelo is proud to announce that Diveedi LAB, Michelangelo
In HER2+ breast cancer patients a neoadjuvant therapy with a
Palbociclib added to standard therapy improved progression-free survival in hormone
Clinical benefits on disease-free survival and overall survival with the
Addition of camrelizumab to neoadjuvant chemotherapy significantly improves pathological complete
Addition of carboplatin to sequential taxane-anthracycline neoadjuvant therapy increased overall
Tucatinib added to trastuzumab and pertuzumab improved progression-free survival in
In the ASCENT-03 trial sacituzumab govitecan as first-line therapy showed
New results from lidERA trial show a significant improvement in
Adjiuvant abemaciclib added to endocrine therapy improves overall survival in
During the Joint International Conference 2025 Innovation in Oncology organized
Final overall survival data from SOLTI-1303-PATRICIA trial highlight the relevance
By analyzing data from the NeoTRIP trial, tumor-specific MHC-II expression
Milan to host the Joint International Conference 2025 on New
SERENA-6 trial shows a longer progression-free survivAal with camizestrant added
Final results from the IMpassion031 trial confirm that adding atezolizumab
In ER-positive, HER2-negative advanced breast cancer vepdegestrant led to significantly
Inavosilib plus palbociclib-fulvestrant led to a significant survival benefit versus
The third generation HER2-directed antibody-drug conjugate trastuzumab rezetecan showed robust
A new nonrandomized clinical trial shows that avoidance of breast
A new phase 3 trial demonstrated clinically meaningful improvements in
Whole genome sequencing-powered ctDNA sequencing improves detection at baseline and
The duration of prior CDK4/6 inhibitor therapy and the presence
Analysis of molecular data from the NA-PHER2 trial, led by
A phase 2 basket trial shows a clinically meaningful antitumor
Results from the SERENA-2 trial show a significant benefit in
Adding inavosilib to palbociclib and fulvestrant increases progression-free survival in
Researchers from Fondazione Michelangelo and Milan-Bicocca University developed and validated
The addition of atezolizumab to pertuzumab plus high-dose trastuzumab doesn’t
The 27-gene signature DetermaIO characterizing the tumor immune microenvironment was
Many trials fail to produce results and to translate into
Postdiagnosis/pretreatment exercise may lower risk of recurrence of breast cancer,
With a longer follow-up of 41 months, trastuzumab-deruxtecan continues to
A retrospective analysis of patients treated with locoregional therapy but
A PET-based, pathological complete response-adapted strategy leads to excellent 3-year
In the phase II aceIERA trial, giredestrant was well tolerated
Addition of palbociclib to fulvestrant did not improve progression-free survival,
With the passing of Pinuccia Valagussa, co-founder of the Michelangelo
A new review from Italian researchers summarizes evidence of efficacy
The final analysis of phase III PEONY trial confirms a
Results from the NATALEE trial show disease-free survival benefits with
INAVO120 trial primary analysis shows benefits with inavosilib added to
Higher pathologic complete response rate with atezolizumab added to anthracycline
A phase I/II trial shows that this HER3-targeted antibody-drug conjugate
An individual patient data metanalysis suggests that oral SERDs improve
A study from Michelangelo Foundation researchers in collaboration with San
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a
Foundation’s experts and data in key educational sessions to share
This multicentric machine learning model improves performance of local models